Related Experiment Video

Updated: Jun 21, 2026

Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease with Fibrosis
06:26

Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease with Fibrosis

Published on: July 18, 2025

Hepatic expression of cell death-inducing DFFA-like effector C in obese subjects is reduced by marked weight loss

Angela M Hall1, Elizabeth M Brunt, Samuel Klein

  • 1Center for Human Nutrition, Department of Medicine, Washington University School of Medicine, St Louis, Missouri, USA.

Obesity (Silver Spring, Md.)
|August 8, 2009
PubMed

Insights

Obesity increases hepatic expression of CIDEA and CIDEC genes in humans. Weight loss significantly reduces CIDEC gene expression, suggesting its role in obesity-related liver changes.

Area of Science:

  • Hepatology
  • Molecular Biology
  • Obesity Research

Background:

  • The cell death-inducing DNA fragmentation factor A-like effector (CIDE) family genes (CIDEA, CIDEB, CIDEC) are upregulated in mouse models of obesity.
  • Understanding CIDE gene expression in human obesity is crucial for metabolic disease research.

Purpose of the Study:

  • To investigate the expression of CIDEA, CIDEB, and CIDEC genes in the liver of obese humans.
  • To determine the correlation between CIDE gene expression and BMI.
  • To assess the impact of significant weight loss on CIDE gene expression.

Main Methods:

  • Liver biopsies were obtained from obese subjects undergoing gastric bypass surgery.
  • Gene expression levels of CIDEA, CIDEB, and CIDEC were measured at baseline and 1 year post-surgery.
  • Statistical analysis was performed to correlate gene expression with BMI and weight loss.

Main Results:

  • CIDEA and CIDEC expression correlated significantly with BMI in obese subjects at the time of surgery.
  • CIDEB expression did not show a significant correlation with BMI.
  • One year after gastric bypass surgery and significant weight loss, CIDEC expression decreased by over 60%, while CIDEA expression remained unchanged.

Conclusions:

  • Hepatic expression of CIDEA and CIDEC is elevated in obese humans, mirroring findings in rodent models.
  • CIDEC expression is significantly downregulated following substantial weight loss.
  • These findings highlight the potential role of CIDEC in human obesity and its modulation by weight reduction.

More Related Videos

An Advanced Murine Model for Nonalcoholic Steatohepatitis in Association with Type 2 Diabetes10:17

An Advanced Murine Model for Nonalcoholic Steatohepatitis in Association with Type 2 Diabetes

Published on: April 26, 2019

Isolation, Characterization, and Purification of Macrophages from Tissues Affected by Obesity-related Inflammation07:46

Isolation, Characterization, and Purification of Macrophages from Tissues Affected by Obesity-related Inflammation

Published on: April 3, 2017

Related Concept Videos

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
Obesity01:24

Obesity

The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in adipocytes...
Cell Specific Gene Expression01:58

Cell Specific Gene Expression

Multicellular organisms contain a variety of structurally and functionally distinct cell types, but the DNA in all the cells originated from the same parent cells. The differences in the cells can be attributed to the differential gene expression. Liver cells, whose functions include detoxification of blood, production of bile to metabolize fats, and synthesis of proteins essential for metabolism, must express a specific set of genes to perform their functions. Gene expression also varies with...